Business Context and Reporting Period
This Form 8-K was filed by Entero Therapeutics, Inc. (not Gridai Technologies Corp.) on October 17, 2025. The report details the entry into a Material Definitive Agreement involving a private placement offering. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol ENTO.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Promissory Notes and Common Stock Purchase Warrants.
- Total Offering Capacity: Up to $5,000,000 in gross proceeds.
- Initial Closing Proceeds: $500,000 received on October 17, 2025.
- Debt Instrument: $500,000 principal amount Promissory Note (non-convertible, non-interest bearing).
- Equity Instrument: Warrant to purchase up to 200,000 shares of common stock (Initial Closing) with a maximum aggregate of 1,520,000 shares if the full $5,000,000 is raised.
- Warrant Exercise Price: $2.50 per share (subject to adjustments).
- Use of Proceeds: General corporate purposes, including working capital and potential acquisitions.
Material Changes and Terms
The filing represents a new material financial obligation and potential equity dilution. Key terms include:
- Note Maturity: One year and one day from issuance, with an option to extend in increments of one year and one day indefinitely.
- Default Events: Failure to pay principal within five business days of due date or occurrence of a Bankruptcy Event.
- Warrant Conditions: Exercisable only after stockholder approval. Expires five years from the approval date. Includes a 4.9% beneficial ownership limitation.
- Registration Rights: The Company agreed to file a registration statement for the resale of Warrant Shares as soon as practicable.
Outlook, Risks, and Management Commentary
- Management Action: The Company must hold a shareholder meeting to obtain approval for the Warrant exercise as soon as practicable. If approval is not obtained, meetings must be called every 90 days until approval is secured or the Warrant expires.
- Future Closings: The agreement permits subsequent closings to raise the remaining balance of the $5,000,000 offering.
- Risks: Potential dilution of existing shareholders upon warrant exercise; obligation to service debt upon maturity; uncertainty regarding the timing of stockholder approval.
Investor Verification Checklist
- Verify the exact number of shares outstanding to calculate the potential dilution impact of the 1,520,000 maximum Warrant Shares.
- Confirm the date and outcome of the upcoming shareholder meeting required for Warrant exercisability.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification provisions.
- Monitor subsequent filings to determine if additional closings occur to reach the $5,000,000 total offering amount.
- Check the company's current cash position to assess the necessity of this financing for working capital.